Azenta, Inc. - Common Stock (NQ:AZTA)

40.06 -1.21 (-2.93%)

Delayed Quote Updated: 10:07 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Reasons AZTA is Risky and 1 Stock to Buy Instead

March 27, 2025

Shareholders of Azenta would probably like to forget the past six months even happened. The stock dropped 23.7% and now trades at $37.66. This might have investors contemplating their next move.

Via StockStory

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 26, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...

Via StockStory

Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks

March 25, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.

Via StockStory

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

A Glimpse Into The Expert Outlook On Azenta Through 4 Analysts ↗

February 06, 2025

Via Benzinga

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

March 18, 2025

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.

Via StockStory

Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,...

Via StockStory

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

March 12, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

1 Small-Cap Stock with Exciting Potential and 2 to Brush Off

March 11, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Topics Supply Chain

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

A Look Ahead: Azenta's Earnings Forecast ↗

November 11, 2024

Via Benzinga

Decoding 5 Analyst Evaluations For Azenta ↗

July 02, 2024

Via Benzinga

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 11, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...

Via StockStory

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

March 05, 2025

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.

Via StockStory

What To Expect From Fortrea’s (FTRE) Q4 Earnings

March 02, 2025

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Via StockStory

UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 24, 2025

Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

The Analyst Landscape: 7 Takes On Azenta ↗

May 09, 2024

Via Benzinga

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

February 19, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Via StockStory

Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow

February 18, 2025

Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know.

Via StockStory

West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For

February 12, 2025

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect

February 09, 2025

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect.

Via StockStory

Azenta’s (NASDAQ:AZTA) Q4 Sales Top Estimates

February 05, 2025

Life sciences company Azenta (NASDAQ:AZTA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, but sales fell by 4.4% year on year to $147.5 million. Its non-GAAP profit of $0.05 per...

Via StockStory

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday? ↗

February 05, 2025

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.

Via Benzinga

Illumina (ILMN) Reports Earnings Tomorrow: What To Expect

February 05, 2025

Genomics company Illumina (NASDAQ:ILMN) will be reporting results tomorrow after the bell. Here’s what investors should know.

Via StockStory

IQVIA (IQV) Q4 Earnings Report Preview: What To Look For

February 05, 2025

Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for.

Via StockStory

Quantum Computing, BlackBerry And Lucid Group Are Among Top Mid Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

The top nine mid-cap stocks from the last week are: Quantum Computing Inc., BlackBerry Limited, IonQ, Inc., Rigetti Computing, Inc., SoundHound AI, Inc., Xometry, Inc., Lucid Group, Inc., Oklo Inc.,...

Via Benzinga

Topics Artificial Intelligence

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday ↗

November 20, 2024

Via Benzinga

AZTA Stock Earnings: Azenta Beats EPS, Beats Revenue for Q3 2024 ↗

August 06, 2024

AZTA stock results show that Azenta beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.

Via InvestorPlace

Stock Market Crash Warning: Don’t Get Caught Holding These 3 Robotics Stocks ↗

May 14, 2024

Despite the promises of the robotics industry, there are key robotics stocks to sell as the market remains volatile.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.